Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lavage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    167 result(s) found for: Lavage. Displaying page 7 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2019-002488-91 Sponsor Protocol Number: MO39874 Start Date*: 2019-11-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATI...
    Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SI (Completed) FR (Completed) HU (Completed) SK (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001263-85 Sponsor Protocol Number: SAV006-05 Start Date*: 2021-07-19
    Sponsor Name:Savara ApS
    Full Title: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP).
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IE (Trial now transitioned) DE (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005277-35 Sponsor Protocol Number: A8851021 Start Date*: 2009-02-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION
    Medical condition: INVASIVE CANDIDIA INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003114-10 Sponsor Protocol Number: NI-0501-09 Start Date*: 2018-09-06
    Sponsor Name:Swedish Orphan Biovitrum AG
    Full Title: An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life...
    Medical condition: Primary Hemophagocytic Lymphohistiocytosis (pHLH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10071583 Haemophagocytic lymphohistiocytosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004024-29 Sponsor Protocol Number: MO39196 Start Date*: 2017-06-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS ...
    Medical condition: Triple Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) FR (Completed) ES (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002265-60 Sponsor Protocol Number: F-FR-58800-003 Start Date*: 2017-08-30
    Sponsor Name:Ipsen Pharma
    Full Title: EFFICACY, SAFETY AND TOLERABILITY OF A BOWEL CLEANSING PREPARATION (EZICLEN®/IZINOVA®) IN PAEDIATRIC SUBJECTS UNDERGOING COLONOSCOPY: A PHASE III, MULTICENTRE, RANDOMISED, COMPARATIVE STUDY VERSUS ...
    Medical condition: Routinely accepted indication for undergoing colonoscopy, including but not limited to polyposis coli diagnosis or surveillance, gastrointestinal bleeding, unexplained diarrhoea or constipation, su...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10010007 Colonoscopy PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005275-10 Sponsor Protocol Number: A1501080 Start Date*: 2009-03-24
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS...
    Medical condition: Treatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003488 Aspergillosis LLT
    9.1 10051919 Fusarium infection LLT
    9.1 10059045 Scedosporium infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) DE (Completed) BG (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000450-21 Sponsor Protocol Number: MONS4STRAT Start Date*: 2018-04-09
    Sponsor Name:Fundación Investigación Biomédica Hospital Ramón y Cajal
    Full Title: Prospective, Randomized, Open, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated,...
    Medical condition: Nosocomial pneumonia or severe tracheobronchitis caused by Gram-negative pathogens in subjects that requiring mechanical ventilation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005348-28 Sponsor Protocol Number: ARD-3150-1201 Start Date*: 2014-05-06
    Sponsor Name:Aradigm Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subje...
    Medical condition: Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10057582 Lung infection pseudomonal PT
    18.0 100000004855 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) LV (Completed) RO (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000050-10 Sponsor Protocol Number: FORMaT001 Start Date*: 2023-01-02
    Sponsor Name:University of Queensland
    Full Title: Finding the Optimal Regimen for Mycobacterium abscessus Treatment
    Medical condition: Mycobacterium abscessus pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10064789 Mycobacterium abscessus infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005726-15 Sponsor Protocol Number: 217102 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with...
    Medical condition: Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10078117 Eosinophilic granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005905-79 Sponsor Protocol Number: OSI-774-203 Start Date*: 2007-03-13
    Sponsor Name:OSI Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumo...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004039-37 Sponsor Protocol Number: CE01-203 Start Date*: 2014-10-10
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ...
    Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2006-004722-82 Sponsor Protocol Number: CSTI571E2204 Start Date*: 2006-11-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to T...
    Medical condition: Seasonal Allergic Rhinitis (sensitivity to Timothy grass pollen)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001565-33 Sponsor Protocol Number: CTBM100C2403 Start Date*: 2013-06-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment...
    Medical condition: Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    17.1 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004598-83 Sponsor Protocol Number: 54371254 Start Date*: 2008-10-22
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous S...
    Medical condition: Severe systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021858-20 Sponsor Protocol Number: PPH/00071/10 Start Date*: Information not available in EudraCT
    Sponsor Name:PALAU PHARMA, S.A.
    Full Title: DOUBLE BLIND RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PROOF OF ACTIVITY STUDY OF UR-63325 IN ALLERGIC RHINITIS INDUCED BY NASAL CHALLENGE TO ALLERGIC PATIENTS OTHERWISE HEALTHY.
    Medical condition: Male subjects with seasonal allergic rhinitis to grass but otherwise healthy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002855-13 Sponsor Protocol Number: CAP-01-102 Start Date*: 2014-02-14
    Sponsor Name:Cardeas Pharma
    Full Title: A Randomized Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered via the Investigational eFlow® Inline System in Mechanically Ventilated...
    Medical condition: Gram-negative Bacterial Pneumonia in Mechanically Ventilated Patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) GR (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002271-97 Sponsor Protocol Number: F901318C21 Start Date*: 2017-04-07
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing che...
    Medical condition: Invasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000919-33 Sponsor Protocol Number: F901318C20 Start Date*: 2016-10-12
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of intravenous and oral F901318 (combined with caspofungin) for antifungal prophylaxis in patients undergoing chem...
    Medical condition: Infasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:25:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA